Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A17: Pembrolizumab + Cisplatin + Pemetrexed in Treatment-naive Advanced Malignant Pleural Mesothelioma
jRCT2080224966Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in pleural mesothelioma, sponsored by Merck & Co. Primary endpoint: Safety and tolerability of pembrolizumab + cisplatin + pemetrexed. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2080224966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224966.